Publications dans lesquelles il/elle collabore avec Dóra Koller (22)

2021

  1. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling

    Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270

  2. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B∗ 57:01 genotyping to predict abacavir hypersensitivity reaction in Spain

    Pharmacogenetics and Genomics, Vol. 31, Núm. 3, pp. 53-59

  3. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers

    Biomedicine and Pharmacotherapy, Vol. 133

  4. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

    Advances in Therapy, Vol. 38, Núm. 2, pp. 1035-1054

  5. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial

    Human Psychopharmacology, Vol. 36, Núm. 1, pp. 1-12

2020

  1. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran

    Advances in Therapy, Vol. 37, Núm. 8, pp. 3537-3550

  2. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates

    Biomedicines, Vol. 8, Núm. 4

  3. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 126, Núm. 3, pp. 236-246

  4. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19)

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1023-1033

  5. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics

    Pharmacogenomics, Vol. 21, Núm. 10, pp. 663-675

  6. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 10, pp. 2051-2062

2019

  1. Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally

    Advances in Therapy, Vol. 36, Núm. 10, pp. 2744-2755

  2. Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure

    Clinical Pharmacology and Therapeutics, Vol. 105, Núm. 3, pp. 661-671

  3. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention

    Clinical Therapeutics, Vol. 41, Núm. 6, pp. 1199-1212.e2

  4. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 3, pp. 321-329

  5. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics

    Journal of Psychopharmacology, Vol. 33, Núm. 4, pp. 522-531

  6. Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation

    Talanta, Vol. 198, pp. 159-168

2018

  1. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants

    Basic and Clinical Pharmacology and Toxicology, Vol. 123, Núm. 4, pp. 474-485

  2. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers

    Basic and Clinical Pharmacology and Toxicology, Vol. 122, Núm. 5, pp. 501-511

  3. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects

    Journal of Psychopharmacology, Vol. 32, Núm. 11, pp. 1212-1222